Dr Jonathan Louw, MB.ChB, MBA, is the CEO of the South African National Blood Service (SANBS), which caters to the entire value chain of blood donation, testing and logistics through transfusion to patients across South Africa. SANBS has 185 sites, 2700 staff and a turnover over R3bn. Previously he was Managing Director at the largest private equity firm in the Middle East. He was also the Co-CEO for the Global Healthcare Fund (in the Dubai headquarter office), raising and deploying $1bn in Hospitals and Diagnostics in global growth markets.
Prior to this, Dr Louw was the CEO and Managing Director at Adcock Ingram Holdings Limited from 2001 until 2014. Dr Louw led the IPO of Adcock Ingram when it separated from the JSE-Listed TigerBrands in 2008 and during his tenure the business adopted an aggressive growth strategy, re-investing in manufacturing and R&D to achieve FDA and PIC/s accreditation in both. Dr Louw first joined the pharmaceutical industry through AstraZeneca in 2000.
He practised as an Anaesthetist at St. Mary's Hospital in London, having trained as an undergraduate at the University of Cape Town in the faculty of Medicine. He has also served as the President of the Pharmaceutical Industry Association of South Africa in 20009/10, representing the interest of local and multi-national pharmaceutical companies, and is a Board member of Generation Ubuntu (NYC) looking after Orphans afflicted with HIV/AIDS in South Africa.